Evaluation of Aphrodisiac Activity of VigRX™

This controlled preclinical study, conducted by Natural Remedies Pvt. Ltd. (Bangalore, India) in male albino Wistar rats, was designed to systematically evaluate the aphrodisiac properties of VigRX across multiple behavioral and physiological dimensions. Using a blinded, multi-dose, 14-day protocol with a positive testosterone control, the study provides rigorous evidence of VigRX's ability to enhance sexual motivation, performance, and recovery.

Study Design

Male albino Wistar rats were divided into groups receiving VigRX at three doses — 225, 335, and 450 mg/kg body weight — a vehicle control (demineralized water), or a testosterone positive control, orally for 14 consecutive days (10 mL/kg dose volume). Sexual behavior was assessed in a blinded four-quadrant mating arena under dim red illumination on Days 0, 1, 7, and 14. Parameters recorded included mount latency, mount frequency, intromission latency, intromission frequency, ejaculation latency, ejaculation frequency, and post-ejaculatory interval. Serum testosterone was measured on Day 15, and testes, epididymides, and seminal vesicles were collected for histopathology.

Key Behavioral Results — Day 14

By Day 14, VigRX produced statistically significant reductions in ejaculation latency at all three doses (225, 335, and 450 mg/kg, p<0.05) — indicating faster time to orgasm and enhanced sexual responsiveness comparable to the testosterone positive control. Post-ejaculatory interval was also significantly reduced at all doses on Day 14 (p<0.05), meaning treated animals recovered and were ready for subsequent sexual activity substantially faster than controls — a key indicator of sexual vitality.

Key Behavioral Results — Higher Dose Effects

At the highest dose tested (450 mg/kg), VigRX additionally demonstrated a significant reduction in mount latency on Day 14 (p<0.05), indicating enhanced sexual motivation and initiation. Intromission latency was significantly reduced at 450 mg/kg on both Days 7 and 14 (p<0.05). Ejaculation frequency showed a significant increase on Day 7 at 450 mg/kg (p<0.05), consistent with the performance profile of the testosterone positive control group.

Testosterone and Histopathology

VigRX at 335 and 450 mg/kg produced a marginal increase in serum testosterone concentration relative to vehicle control. Histopathological evaluation of testes, epididymides, and seminal vesicles revealed no significant changes between treated and control groups, confirming VigRX's favorable safety profile at all doses tested.

Conclusion

VigRX demonstrated genuine, multi-dimensional aphrodisiac activity in a rigorous controlled study — significantly reducing ejaculation latency and post-ejaculatory interval at all tested doses, and enhancing mount latency, intromission latency, and ejaculation frequency at higher doses. These effects closely parallel those of the testosterone positive control, providing compelling evidence that VigRX supports the full spectrum of male sexual motivation, performance, and recovery through natural mechanisms.

Click here to read the full report →
Explore the complete VigRX product line →